scPharmaceuticals ( NASDAQ: SCPH ) on Monday announced non-dilutive financings totaling up to $125M with funds managed by Perceptive Advisors. Proceeds from the transactions will be used to repay existing debt, as well as to fund activities related to the ongoing commercialization of FUROSCIX. The company received $75M through a combination of debt and royalty financings at close, with access to an additional $50M.
The term loan refinances existing debt principal; lowers coupon, extends interest-only period for four additional years, and lowers minimum cash requirement to $5M. Press release. More on scPharmaceuticals scPharmaceuticals gets %125M funding from Perceptive Advisors Seeking Alpha’s Quant Rating on scPharmaceuticals Historical earnings data for scPharmaceuticals Financial information for scPharmaceuticals.
